• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Vonoprazan: MarKed Competition for PPIs?沃克帕唑：对质子泵抑制剂构成显著竞争？
Dig Dis Sci. 2016 Jul;61(7):1783-4. doi: 10.1007/s10620-016-4164-8.
2
Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.新型钾离子竞争性酸阻滞剂沃诺拉赞是否比传统质子泵抑制剂引起更多的高胃泌素血症？一项多中心前瞻性横断面研究。
Digestion. 2018;97(1):70-75. doi: 10.1159/000484217. Epub 2018 Feb 1.
3
Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy.比较研究：沃克帕唑与质子泵抑制剂在根除治疗中的应用
World J Gastroenterol. 2017 Jan 28;23(4):668-675. doi: 10.3748/wjg.v23.i4.668.
4
The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.沃克帕唑（TAK-438）对胃H⁺，K⁺ -ATP酶的结合选择性。
Aliment Pharmacol Ther. 2015 Dec;42(11-12):1315-26. doi: 10.1111/apt.13414. Epub 2015 Sep 30.
5
Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.沃诺拉赞，一种新型钾离子竞争型酸阻滞剂，应作为幽门螺杆菌根除治疗的首选药物：一项使用沃诺拉赞的真实世界大样本研究与我们使用第二代质子泵抑制剂进行的幽门螺杆菌根除治疗的随机对照试验比较。
Digestion. 2018;97(3):212-218. doi: 10.1159/000485097. Epub 2018 Jan 31.
6
Vonoprazan May Provide Better Results than PPIs in Helicobacter Pylori Eradication and Beyond - Is it Time for a Change?沃克帕唑在根除幽门螺杆菌及其他方面可能比质子泵抑制剂产生更好的效果——是时候做出改变了吗？
J Gastrointestin Liver Dis. 2019 Dec 9;28(4):375-377. doi: 10.15403/jgld-573.
7
Vonoprazan fumarate for the management of acid-related diseases.富马酸沃克索拉唑用于治疗酸相关性疾病。
Expert Opin Pharmacother. 2017 Aug;18(11):1145-1152. doi: 10.1080/14656566.2017.1346087. Epub 2017 Jul 6.
8
The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.换用新型钾离子竞争性酸阻滞剂沃克瑞对质子泵抑制剂难治性糜烂性食管炎患者胃酸分泌及反流模式的影响
Digestion. 2017;96(1):52-59. doi: 10.1159/000478255. Epub 2017 Jun 30.
9
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.沃克预防内镜黏膜下剥离术所致胃溃疡出血。
Aliment Pharmacol Ther. 2016 Sep;44(6):583-91. doi: 10.1111/apt.13747. Epub 2016 Jul 28.
10
Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.在健康成年男性受试者中，与埃索美拉唑 20mg 或雷贝拉唑 10mg 相比，沃诺拉赞 20mg 的抑酸作用——一项随机、开放标签交叉研究。
Aliment Pharmacol Ther. 2015 Sep;42(6):719-30. doi: 10.1111/apt.13325. Epub 2015 Jul 21.

引用本文的文献

1
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.评价含铋四联疗法（沃诺拉赞或兰索拉唑）根除幽门螺杆菌的安全性和药代动力学。
Br J Clin Pharmacol. 2022 Jan;88(1):138-144. doi: 10.1111/bcp.14934. Epub 2021 Jun 26.

本文引用的文献

1
Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.新型钾离子竞争性酸阻滞剂沃克在大鼠胃黏膜中的影像学定位研究
Dig Dis Sci. 2016 Jul;61(7):1888-94. doi: 10.1007/s10620-016-4100-y. Epub 2016 Mar 9.
2
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.随机临床试验：新型钾离子竞争性酸阻滞剂沃克替尼与兰索拉唑治疗糜烂性食管炎的剂量范围研究。
Aliment Pharmacol Ther. 2015 Sep;42(6):685-95. doi: 10.1111/apt.13331. Epub 2015 Jul 22.
3
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.健康日本/非日本男性受试者单次递增剂量TAK-438（沃克拉唑）的安全性、耐受性、药代动力学和药效学
Clin Transl Gastroenterol. 2015 Jun 25;6(6):e94. doi: 10.1038/ctg.2015.18.
4
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).一种新型钾竞争性酸阻滞剂的表征，即 1-[5-(2-氟苯基)-1-(吡啶-3-基磺酰基)-1H-吡咯-3-基]-N-甲基甲胺单富马酸盐（TAK-438）。
J Pharmacol Exp Ther. 2011 Nov;339(2):412-20. doi: 10.1124/jpet.111.185314. Epub 2011 Aug 9.
5
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.TAK-438（一种新型钾离子竞争性酸阻滞剂）与兰索拉唑在原代培养兔胃腺中作用机制的比较研究。
Biochem Pharmacol. 2011 May 1;81(9):1145-51. doi: 10.1016/j.bcp.2011.02.009. Epub 2011 Mar 1.
6
Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.钾离子竞争性酸阻滞剂：酸相关性疾病的一种新治疗策略。
Pharmacol Ther. 2005 Dec;108(3):294-307. doi: 10.1016/j.pharmthera.2005.05.005. Epub 2005 Jul 5.
7
Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.CYP2C19药物遗传学对基于质子泵抑制剂的幽门螺杆菌根除治疗的疗效影响
Methods Find Exp Clin Pharmacol. 2003 Mar;25(2):131-43. doi: 10.1358/mf.2003.25.2.723687.
8
CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.健康受试者中CYP2C19基因型与三种质子泵抑制剂的药代动力学
Pharm Res. 2001 Jun;18(6):721-7. doi: 10.1023/a:1011035007591.
9
Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.
Gastroenterology. 1995 Oct;109(4):1134-41. doi: 10.1016/0016-5085(95)90571-5.
10
Inhibition of gastric H+,K+-ATPase and acid secretion by SCH 28080, a substituted pyridyl(1,2a)imidazole.
J Biol Chem. 1987 Feb 15;262(5):2077-84.

Vonoprazan: MarKed Competition for PPIs?

作者信息

Scott David R, Marcus Elizabeth A, Sachs George

机构信息

Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA.

VA GLAHS, 11301 Wilshire Blvd., Bldg. 113, Rm. 324, Los Angeles, CA, USA.

出版信息

Dig Dis Sci. 2016 Jul;61(7):1783-4. doi: 10.1007/s10620-016-4164-8.

DOI:10.1007/s10620-016-4164-8
PMID:27074922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4920708/
Abstract
摘要